stEPP Study for EPP & XLP

UPA is supporting the patient community and clinical study sites to assist in patient referrals for stEPP, a clinical outcomes assessment study (also referred to as an observational study) that tracks the disease and its impact on individuals living with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). This study is sponsored by Portal Therapeutics.

Participation involves study-related visits with clinicians experienced in your condition and contributes to future research. Your participation in stEPP will help inform the design of future clinical studies, including those involving investigational therapies.